Eli Lilly Financial Statements
Eli Lilly Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
Eli Lilly Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 20,378.0 | 18,633.5 | 15,691.0 |
| Gross Profit ($ mil.) | 15,995.2 | 14,384.7 | 12,144.5 |
| Operating Income ($ mil.) | (1,079.3) | 4,105.1 | 3,656.1 |
| Total Net Income ($ mil.) | (2,071.9) | 2,953.0 | 2,662.7 |
| Diluted EPS (Net Income) | (1.89) | 2.71 | 2.45 |
Eli Lilly Quarterly Statements
| Quarter Ending Sep 09 | Quarter Ending Jun 09 | Quarter Ending Jun 09 | |
|---|---|---|---|
| Revenue ($ mil.) | 5,562.0 | 5,292.8 | 5,292.8 |
| Gross Profit ($ mil.) | 4,510.1 | 4,345.4 | 4,345.4 |
| Operating Income ($ mil.) | 1,128.7 | 1,532.0 | 1,532.0 |
| Total Net Income ($ mil.) | 941.8 | 1,158.5 | 1,158.5 |
| Diluted EPS (Net Income) | 0.86 | 1.06 | 1.06 |
Eli Lilly Stock Quote & Chart
11/06/09 16:01:07 EST •
NYSE •
34.50
•
 +0.0700
•
+0.2033 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Eli Lilly Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 1.79 | 2.58 | 7.01 |
| Price/Earnings Ratio | (175.44) | 16.39 | 25.51 |
| Price/Book Ratio | 4.00 | 2.81 | 6.74 |
| Price/Cash Flow Ratio | 8.05 | 9.89 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Eli Lilly Financial Ratios
Eli Lilly Competitive Intelligence
| GlaxoSmithKline | Novo Nordisk | Pfizer | |
|---|---|---|---|
| Annual Sales ($ mil.) | 35,244.6 | 8,627.7 | 48,296.0 |
| Employees | 99,003 | 26,600 | 81,800 |
| Market Cap ($ mil.) | 114,528.4 | 40,937.4 | 114,870.4 |
Competitive Landscape
